azd5148
mAbexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 24, 2024 (NCT06469151)
Timeline
Indications
Mechanism of action
- Toxin BINHIBITOR
tcdB inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07285213 | Phase 2 | Dec 10, 2025 | AstraZeneca |
| NCT06639997 | Phase 1 | Oct 30, 2024 | AstraZeneca |
| NCT06469151 | Phase 1 | Jun 24, 2024 | AstraZeneca |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 3 | 3 | 2 | 2024 |
1 organizations
Page 1 / 1